Table 1.
Baseline demographics and treatment details.
| Characteristic | Standard (N = 43) | Hypofractionated (N = 19) | All (N = 62) | |
|---|---|---|---|---|
| Age (years) | 74 (70–88) | 77 (71–91) | 74 (70–91) | |
| Sex | Female | 17 (40) | 11 (58) | 28 (45) |
| Male | 26 (61) | 8 (42) | 34 (55) | |
| Maximal resection | GTR | 26 (61) | 7 (37) | 33 (53) |
| STR | 7 (16) | 3 (16) | 10 (16) | |
| Biopsy only | 10 (23) | 9 (47) | 19 (31) | |
| KPS | ≥70 | 32 (74) | 12 (63) | 44 (71) |
| <70 | 6 (14) | 4 (22) | 10 (16) | |
| Unknown | 5 (12) | 3 (16) | 8 (13) | |
| MGMT | Methylated | 13 (30) | 7 (37) | 20 (32) |
| Unmethylated | 18 (42) | 8 (42) | 26 (42) | |
| Unknown | 12 (28) | 4 (21) | 16 (26) | |
| Radiation technique | 3D | 4 (9) | 9 (47) | 13 (21) |
| IMRT | 39 (91) | 10 (53) | 49 (79) | |
| GTV initial (cm3) | 98 (8–283) | 27 (6–137) | ||
| GTV boost (cm3) | 31 (7–165) | |||
| PTV initial (cm3) | 459 (121–1,049) | 238 (85–505) | ||
| PTV boost (cm3) | 181 (78–410) | |||
| Concurrent TMZ | Yes | 43 (100) | 15 (79) | 58 (94) |
| No | 0 (0) | 4 (21) | 4 (6) | |
| Concurrent bevacizumab | Yes | 13 (30) | 7 (37) | 20 (32) |
| No | 30 (70) | 12 (63) | 42 (68) | |
| Completed RT | Yes | 37 (86) | 17 (90) | 54 (87) |
| No | 6 (14) | 2 (10) | 8 (13) |
KPS, Karnofsky Performance Status; MGMT, O6-methylguanine DNA methyltransferase; GTV, gross target volume; PTV, planning target volume; TMZ, temozolomide; RT, radiation therapy.
Data show number (%) or median (range).